Prostate News Archive
10-Oct-2008
Watson Wins U.S. Approval for New Prostate Treatment (Update1) (Bloomberg)
Oct. 8 (Bloomberg) -- Watson Pharmaceuticals Inc. won U.S. approval to sell a prostate enlargement treatment as the drugmaker expands beyond manufacturing generic medicines. Center For Prostate Disease Research Reports New Prognostic Utility Of PCA3 Molecular Urine Test (Medical News Today)
In a recent report, the collaborative research team from the Center for prostate Disease Research at the Uniformed Services Universit of the Health Sciences (USU) and Walter Reed Army Medical Center (WRAMC) and Gen-Probe Inc., San Diego, Calif., showed a new promising prognostic utility of the urine PCA3 test. The study was co-led by Drs. David G. McLeod and Shiv Srivastava from CPDR and Drs. DGCRF: PCA3 Prostate Cancer Test Featured in Journal of Urology (Nasdaq)
DiagnoCure Inc. (DGCRF) announced that PCA3, the Company's highly specific prostate cancer marker, is featured in an article in the November issue of the Journal of Urology. The new published study supports the use of a PCA3-based test as a tool for better assessing the prognosis of prostate cancer. New risk factor for prostate cancer (PhysOrg)
(PhysOrg.com) -- The greater the levels of a protein called Insulin-like Growth Factor-1 (IGF-1), the greater the risk of prostate cancer, an Oxford University-led study has found. The results are published in the journal Annals of Internal Medicine. Prostate Meds Not Tied to Increased Hip Fracture Risk (HealthDay via Yahoo! News)
TUESDAY, Oct. 7 (HealthDay News) -- A new study found no link between the use of a drug to treat an enlarged prostate and an increase in hip fractures in men.
Back to Prostate News Archive
